{"id":"NCT04083235","sponsor":"Ipsen","briefTitle":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","officialTitle":"An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-11","primaryCompletion":"2022-07-23","completion":"2025-02-18","firstPosted":"2019-09-10","resultsPosted":"2024-03-13","lastUpdate":"2025-02-27"},"enrollment":770,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Adenocarcinoma of the Pancreas"],"interventions":[{"type":"DRUG","name":"Irinotecan Liposomal Injection","otherNames":["Onivyde®","Nal-IRI"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":["Eloxatin®"]},{"type":"DRUG","name":"5Fluorouracil","otherNames":["Adrucil®","flurouracil","5-FU"]},{"type":"DRUG","name":"Leucovorin","otherNames":["Folinic Acid"]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":["Abraxane®"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar®"]}],"arms":[{"label":"Irinotecan liposome injection + Oxaliplatin + 5-FU/LV","type":"EXPERIMENTAL"},{"label":"Nab-paclitaxel + Gemcitabine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter up to DCO date of 23 July 2022 (maximum of 893 days)","effectByArm":[{"arm":"NALIRIFOX","deltaMin":11.1,"sd":null},{"arm":"Nab-paclitaxel+Gemcitabine","deltaMin":9.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.04"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":200,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Portugal","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["37708904"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":201,"n":370},"commonTop":["Diarrhoea","Nausea","Fatigue","Anaemia","Vomiting"]}}